MX2020008676A - Expresion controlada de transgenes mediante el uso de vectores de adn de extremo cerrado (ceadn). - Google Patents
Expresion controlada de transgenes mediante el uso de vectores de adn de extremo cerrado (ceadn).Info
- Publication number
- MX2020008676A MX2020008676A MX2020008676A MX2020008676A MX2020008676A MX 2020008676 A MX2020008676 A MX 2020008676A MX 2020008676 A MX2020008676 A MX 2020008676A MX 2020008676 A MX2020008676 A MX 2020008676A MX 2020008676 A MX2020008676 A MX 2020008676A
- Authority
- MX
- Mexico
- Prior art keywords
- level
- expression
- transgene
- cedna
- close
- Prior art date
Links
- 108700019146 Transgenes Proteins 0.000 title abstract 7
- 239000013598 vector Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 230000037452 priming Effects 0.000 abstract 2
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000004448 titration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/50—Vectors for producing vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862633882P | 2018-02-22 | 2018-02-22 | |
| US201862633795P | 2018-02-22 | 2018-02-22 | |
| US201862633757P | 2018-02-22 | 2018-02-22 | |
| US201862746762P | 2018-10-17 | 2018-10-17 | |
| PCT/US2019/018927 WO2019165050A1 (en) | 2018-02-22 | 2019-02-21 | Controlled expression of transgenes using close-ended dna (cedna) vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008676A true MX2020008676A (es) | 2020-09-25 |
Family
ID=67687406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008676A MX2020008676A (es) | 2018-02-22 | 2019-02-21 | Expresion controlada de transgenes mediante el uso de vectores de adn de extremo cerrado (ceadn). |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220175970A1 (https=) |
| EP (1) | EP3755803A4 (https=) |
| JP (2) | JP2021513999A (https=) |
| KR (1) | KR20200124250A (https=) |
| CN (1) | CN111886343A (https=) |
| AU (1) | AU2019225937A1 (https=) |
| BR (1) | BR112020017060A2 (https=) |
| CA (1) | CA3092059A1 (https=) |
| IL (1) | IL276658A (https=) |
| MA (1) | MA51915A (https=) |
| MX (1) | MX2020008676A (https=) |
| PH (1) | PH12020551235A1 (https=) |
| SG (1) | SG11202007621TA (https=) |
| WO (1) | WO2019165050A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ762100A (en) | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| EP3833766A1 (en) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| KR20210090619A (ko) * | 2018-11-09 | 2021-07-20 | 제너레이션 바이오 컴퍼니 | 대칭인 변형된 역말단반복을 포함하는 변형된 폐쇄형 DNA(ceDNA) |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| JP2023520763A (ja) * | 2020-03-24 | 2023-05-19 | ジェネレーション バイオ カンパニー | ゴーシェ治療薬を発現するための非ウイルス性ｄｎａベクター及びその使用 |
| US20230138409A1 (en) * | 2020-03-24 | 2023-05-04 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing factor ix therapeutics |
| EP4142758A4 (en) * | 2020-04-28 | 2025-02-26 | President and Fellows of Harvard College | High efficiency gene delivery system |
| IL299422A (en) * | 2020-06-26 | 2023-02-01 | Univ Leland Stanford Junior | Targeting the human ccr5 locus as a safe harbor for the expression of therapeutic proteins |
| JP2023535632A (ja) | 2020-07-27 | 2023-08-18 | アンジャリウム バイオサイエンシズ エージー | Ｄｎａ分子の組成物、その作製方法、及びその使用方法 |
| WO2022046665A1 (en) * | 2020-08-23 | 2022-03-03 | Bioverativ Therapeutics Inc. | MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA) |
| EP4214309A4 (en) * | 2020-09-16 | 2025-07-16 | Generation Bio Co | CLOSED-END DNA VECTORS AND RELATED USES FOR EXPRESSING PHENYLALANINE HYDROXYLASE (PAH) |
| CA3211687A1 (en) * | 2021-03-19 | 2022-09-22 | Ozan ALKAN | Non-viral dna vectors and uses thereof for expressing pfic therapeutics |
| WO2025114932A1 (en) * | 2023-11-30 | 2025-06-05 | Sanofi | Purification of closed-ended dna molecules |
| CN121662213B (zh) * | 2026-02-06 | 2026-04-21 | 湖南博极生命科技有限公司 | 基于注意力权重追溯的中药活性成分可解释性分析方法及系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003237805A1 (en) * | 2002-04-09 | 2003-10-27 | Cornell Research Foundation, Inc. | Use of aav integration efficiency element for mediating site-specific integration of a transcription unit |
| HUE041875T2 (hu) * | 2005-05-31 | 2019-06-28 | Univ Colorado Regents | Eljárás génbejuttatásra |
| ES2426091T3 (es) * | 2007-09-19 | 2013-10-21 | Uniqure Ip B.V. | Uso de maquinaria de replicación de AAV para producción de proteína mejorada |
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| EP3151866B1 (en) * | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| JP7242180B2 (ja) * | 2014-09-07 | 2023-03-20 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物 |
| EP3889260A1 (en) * | 2014-12-12 | 2021-10-06 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
| MX2018010633A (es) * | 2016-03-03 | 2019-06-13 | Univ Massachusetts | Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral. |
-
2019
- 2019-02-21 MA MA051915A patent/MA51915A/fr unknown
- 2019-02-21 SG SG11202007621TA patent/SG11202007621TA/en unknown
- 2019-02-21 JP JP2020544445A patent/JP2021513999A/ja active Pending
- 2019-02-21 BR BR112020017060-7A patent/BR112020017060A2/pt not_active Application Discontinuation
- 2019-02-21 US US16/971,016 patent/US20220175970A1/en active Pending
- 2019-02-21 EP EP19757005.4A patent/EP3755803A4/en active Pending
- 2019-02-21 KR KR1020207026566A patent/KR20200124250A/ko not_active Ceased
- 2019-02-21 MX MX2020008676A patent/MX2020008676A/es unknown
- 2019-02-21 AU AU2019225937A patent/AU2019225937A1/en not_active Abandoned
- 2019-02-21 CN CN201980019861.5A patent/CN111886343A/zh active Pending
- 2019-02-21 CA CA3092059A patent/CA3092059A1/en active Pending
- 2019-02-21 PH PH1/2020/551235A patent/PH12020551235A1/en unknown
- 2019-02-21 WO PCT/US2019/018927 patent/WO2019165050A1/en not_active Ceased
-
2020
- 2020-08-11 IL IL276658A patent/IL276658A/en unknown
-
2023
- 2023-12-08 JP JP2023207938A patent/JP2024028931A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3092059A1 (en) | 2019-08-29 |
| CN111886343A (zh) | 2020-11-03 |
| RU2020131041A (ru) | 2022-03-22 |
| WO2019165050A1 (en) | 2019-08-29 |
| BR112020017060A2 (pt) | 2020-12-15 |
| IL276658A (en) | 2020-09-30 |
| US20220175970A1 (en) | 2022-06-09 |
| PH12020551235A1 (en) | 2021-04-19 |
| JP2021513999A (ja) | 2021-06-03 |
| AU2019225937A1 (en) | 2020-08-13 |
| EP3755803A1 (en) | 2020-12-30 |
| EP3755803A4 (en) | 2022-01-19 |
| MA51915A (fr) | 2020-12-30 |
| JP2024028931A (ja) | 2024-03-05 |
| SG11202007621TA (en) | 2020-09-29 |
| KR20200124250A (ko) | 2020-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008676A (es) | Expresion controlada de transgenes mediante el uso de vectores de adn de extremo cerrado (ceadn). | |
| MX2021008874A (es) | Adn de extremo cerrado (ceadn) y uso en metodos de reduccion de la respuesta inmunitaria relacionada con tratamiento genico o de acido nucleico. | |
| PH12021550476A1 (en) | Universal donor cells | |
| MX2019005588A (es) | Metodos para modular corte y empalme de arn. | |
| GB2573664A (en) | Viral methods of T cell therapy | |
| PH12019502529A1 (en) | Materials and methods for engineering cells and uses thereof in immuno-oncology | |
| EA202090034A1 (ru) | Способы модификации сплайсинга рнк | |
| EP4345165A3 (en) | Gene therapy for retinitis pigmentosa | |
| MX2018012729A (es) | Materiales y metodos para el tratamiento de hemoglobinopatias. | |
| MX2019000205A (es) | Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno. | |
| WO2019246544A3 (en) | Vectors for gene delivery that persist within cells | |
| PH12020550748A1 (en) | Synpiii, a promoter for the specific expression of genes in retinal pigment epithelium | |
| AU2015311681A8 (en) | Globin gene therapy for treating hemoglobinopathies | |
| CA3057899A1 (en) | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof | |
| EP3800255A3 (en) | Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain | |
| ZA202006505B (en) | Micro rna expression constructs and uses thereof | |
| EP4491733A3 (en) | Modulation of aav vector transgene expression | |
| MY194058A (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| WO2014179331A3 (en) | Devices, systems and methods for optogenetic modulation of action potentials in target cells | |
| EP4596565A3 (en) | Rna-guided transcriptional regulation | |
| EP4273160A3 (en) | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination | |
| AU2017346788A8 (en) | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules | |
| NZ759034A (en) | Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b | |
| MX2022002663A (es) | Celulas donantes universales. | |
| PH12022550543A1 (en) | Universal donor cells |